(PO01-45-22) β-Nicotinamide Mononucleotide Supplement With Astaxanthin and Blood Orange Enhanced NAD+ Bioavailability and Mitigated Age-Associated Physiological Decline in Zebrafish
Objectives: Reports showed that decreased NAD+ bioavailability was believed to disturb metabolism and cause certain disease conditions in aging animal models. While preclinical evidence suggests β-nicotinamide mononucleotide (NMN), as a key NAD+ intermediate, has shown great potential to enhance NAD+ biosynthesis and ameliorate effects of aging in animal models. The bioavailability of NMN was not satisfying when administrated alone.
Methods: In this study, several NMN compound formulas, combined with other active ingredients, were used in the wild-type zebrafish model to investigate the NAD+ level enhancement and anti-aging effects.
Results: Remarkably, administered NMN with astaxanthin and blood orange (NOA) was quickly utilized to synthesize NAD+ in zebrafishes and was superior to nicotinamide riboside (NR), NR with astaxanthin and blood orange(ROA), NMN with other active ingredients including pterostilbene (NOP) and roxburgh rose (NOR) with no obvious toxic effects demonstrated. Furthermore, formula NOA could effectively resist fatigue, promote physical activity, regulate sleep, and improve skin status, indicating the mitigation of age-associated physiological decline in zebrafish. Consistent with these phenotypes, NOA upregulated gene expression that could exert regulatory effects on sleep and skin status and raised ATP synthesis.
Conclusions: These effects of the formula NOA in the zebrafish model demonstrated its preventive and therapeutic potential as an effective anti-aging intervention to improve human health.